Related Experiment Video
Updated: Jul 10, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
A model for the Dutch pharmaceutical market
1CPB-Netherlands Bureau for Economic Policy Analysis, The Hague, Netherlands. canton@cpb.nl
Health Economics
|September 2, 1999
Summary
This study models the Dutch pharmaceutical market to analyze policy impacts on healthcare costs. General-equilibrium analysis reveals unexpected effects of drug distribution incentives and market competition.
Area of Science:
- Health Economics
- Pharmaceutical Market Analysis
- General Equilibrium Theory
Background:
- The Dutch pharmaceutical market involves complex interactions between patients, pharmacists, drug producers, and parallel-importers.
- Partial-equilibrium approaches may not fully capture the system-wide effects of policy changes in this market.
Purpose of the Study:
- To develop a general-equilibrium model of the Dutch pharmaceutical market.
- To evaluate the impact of various policy interventions on pharmaceutical care expenditures.
Main Methods:
- Microeconomic principles were used to derive the behavior of market actors.
- A calibrated general-equilibrium model was employed for policy simulations.
- Policy experiments included cost-conscious distribution incentives, increased copayments, reduced trade barriers for parallel-importers, and generic drug market entry.
Main Results:
- General-equilibrium effects on pharmaceutical care costs can differ significantly from partial-equilibrium predictions.
- The model quantifies the impact of specific policies on overall healthcare spending.
- Simulations provide insights into the economic consequences of market structure and regulatory changes.
Conclusions:
- A general-equilibrium framework is essential for accurately assessing pharmaceutical market policies.
- Policy interventions can have complex and sometimes counterintuitive effects on healthcare costs.
- The model provides a valuable tool for policymakers in the Netherlands for pharmaceutical market regulation.
Related Concept Videos
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:18Pharmacodynamic Models: Emax Drug–Concentration Effect Model
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).